On this basis, the 2022 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines provided a strong Level 1A recommendation that patients with T2D, CKD, and an eGFR of ≥20 mL/min/1.73 m2 should receive first-line therapy with an SGLT-2 inhibitor, with the indication of cardiorenal protection [7]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.